

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,990
				Filing Date	March 15, 2004
				First Named Inventor	Samuel Broder
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	BAKER 3.0-002 CIP DIV CONT CONT

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)				
RR	AA	US-5,112,817	05-12-1992	Fukazawa et al.	514	183
RR	AB	US-5,114,951	05-00-1992	King	514	290
RR	AC	US-5,118,493	06-00-1992	Kelley et al.	424	10
RR	AD	US-5,124,330	06-00-1992	King	514	250
RR	AE	US-5,124,338	06-00-1992	King	514	343
RR	AF	US-5,124,339	06-00-1992	King	514	352
RR	AG	US-5,166,207	11-00-1992	Smith	514	270
RR	AH	US-5,208-238	05-00-1993	King	514	255
RR	AI	US-5,300,282	04-00-1994	King	424	10
RR	AJ	US-5,346,897	09-00-1994	King	514	290
RR	AK	US-5,364,843	11-00-1994	King	514	15
RR	AL	US-5,387,685	02-00-1995	Powell et al.	546	143
RR	AM	US-5,395,610	03-00-1995	King	424	10
RR	AN	US-5,405,843	04-11-1995	Fukazawa et al.	514	183
RR	AO	US-5,416,091	05-00-1995	King	514	290
RR	AP	US-5,438,072	08-00-1995	Bobee et al.	514	449
RR	AQ	US-5,525,590	06-00-1996	Bollinger et al.	514	11
RR	AR	US-5,646,176	07-00-1997	Golik et al.	514	444
RR	AS	US-5,670,536	09-00-1997	Durr et al.	514	449
RR	AT	US-5,750,561	05-00-1998	Bastart et al.	514	449
RR	AU	US-5,968,972	10-00-1999	Broder et al.	424	449
RR	AV	US-5,972,992	10-00-1999	Carver et al.	514	449
RR	AW	US-6,004,927	12-00-1999	Benet al.	514	9
RR	AX	US-6,096,331	08-00-2000	Desai et al.	424	422
RR	AY	US-6,245,805	06-00-2001	Broder et al.	514	449

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
RR	BA	EP	413828	11-00-1990			
RR	BB	WO	92/12132	07-00-1992			
RR	BC	WO	95/20980	08-00-1995			
RR	BD	WO	9727855	08-00-1997			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>RR Campbell</i>	Date Considered	9-22-04
--------------------	--------------------	-----------------	---------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/800,990
				Filing Date	March 15, 2004
				First Named Inventor	Samuel Broder
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	BAKER 3.0-002 CIP DIV CONT CONT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RR	CA	Duverne, et al., Antimicrobial Agents and Chemotherapy, 36(11):2462-2467 (1992)		
RR	CB	Vinceneux, et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, 24(3):153-158 (1986)		
RR	CC	Benet et al., J. Cont. Release, Vol. 39, pp. 139-143 (1996)		
RR	CD	Brock et al., Cancer Res., Vol. 55, pp. 459-462 (1995)		
RR	CE	Wils et al., Biochem. Pharm., Vol. 48, pp. 1528-1530 (1994)		
RR	CF	Kloke et al., Klin. Wochenschr., Vol. 63, pp. 1081-1082 (1985)		
RR	CG	Chang et al., Clin. Pharm. Therap., Vol. 59, pp. 297-303 (1996)		
RR	CH	Chiu et al., Proc. Of Am. Assoc. Pharm. Sci., Abstract PDD 7428 (Nov. 1995)		
RR	CI	Bal et al., Proc. of Am. Assoc. Pharm. Sci., Abstract PDD 7459 (Nov. 1995)		
RR	CJ	Germann et al., J. Bioenerg. Biomemb., Vol. 27, pp. 53-61 (1995)		
RR	CK	Joel et al., Cancer Chemother. Pharmac., Vol. 37, pp. 125-133 (1995)		
RR	CL	Schinkel et al., J. Clin. Invest., Vol. 96, pp. 1698-1705 (1995)		
RR	CM	Scheffer et al., Nature Medicine, Vol. 1, No. 6, pp. 578-582 (1995)		
RR	CN	Lum et al., Drug Resistance in Clin. Onc. and Hematology, Vol. 9, No. 2, pp. 319-336 (1995)		
RR	CO	Fracasso et al., Proc. of ASCO, Vol. 14, Abstract 1585, p. 486 (1995)		
RR	CP	Bissey, Euro J. Cancer, Vol. 31A, Sup. 4, pp. S1-S6 (1995)		
RR	CQ	Leu et al., Cancer Chem. Pharmac., Vol. 35, No. 5, pp. 432-436 (1995)		
RR	CR	Keogh et al., N.E. J. Med., Vol. 333, No. 10, pp. 628-633 (1995)		
RR	CS	Leveque et al., Anticancer Res. Vol. 15, pp. 331-336 (1995)		
RR	CT	Montaseri et al., Pharm. Res., Vol. 12, No. 9, p. S-429, Abstract PPDM 8411 (1995)		
RR	CU	Muller, Proc. Nat. Acad. Sci., Vol. 91, pp. 13033-13037 (1994)		
RR	CV	Pouvelle et al., J. Clin. Invest., Vol. 94, pp. 413-417 (1994)		
RR	CW	Schinkel et al., Cell, Vol. 77, pp. 491-502 (1994)		
RR	CX	Fisher et al., Proc. of ASCO, Vol. 13, Abstract 369, p. 144 (1994)		
RR	CY	Siegsmond et al., J. Urol., Vol. 151, pp. 485-491 (1994)		
RR	CZ	Grant et al., Cancer Res., Vol. 54, pp. 357-361 (1994)		
RR	CA1	Cresteil et al., Cancer Res., Vol. 54, pp. 386-392 (1994)		
RR	CB1	Bartlett et al., J. Clin. Onc., Vol. 12, No. 4, pp. 835-842 (1994)		
RR	CC1	Sikic et al., Anticancer Drug Resistance: Adv. Molec. Clin. Res., pp. 149-165 (1994)		
RR	CD1	Kumar et al., J. of Pharmac. and Exp. Therapeutics., Vol. 268, No. 3, pp. 1160-1165 (1994)		
RR	CE1	Lepage et al., Current Op. in Neph. And Hypert., Vol. 2, pp. 735-743 (1993)		
RR	CF1	Lum et al., Clin. Onc., Vol. 10, No. 10, pp. 1635-1642 (1992)		
RR	CG1	Loehrer, Seminars in Onc., Vol. 18, No. 6, Sup. 14, pp. 48-52 (1992)		
RR	CH1	Keller et al., Int. J. Cancer, Vol. 51, pp. 433-438 (1992)		
RR	CI1	Hunter et al., Pharma. Res. 10(5):743-749 (1993)		
RR	CJ1	Kobayashi, Proc. Ann. Meet. Am. Soc. Clin. Oncol. 15:A14889 (1996)		
RR	CK1	Harris et al., Cancer Research, 54:4026-35 (1994)		
RR	CL1	Tsuruo, Jpn. J. Cancer Chemotherapy, 21(7):962-67, (1994) (English abstract only)		
RR	CM1	Baba et al., Cancer Chemother. Pharmacol. 36(5):361-67(1995)		
RR	CN1	Terao et al., J. Pharmacy & Pharmacol. 48:1083-1089(1996)		
RR	CO1	Sato, et al., Cancer Chemother. Pharmacol.; 35(4):271-277 (1995)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	<i>RRaymond</i>	Date Considered	9-22-04
--------------------	-----------------	-----------------	---------

